Edwards Lifesciences Corp (NYSE: EW)

$81.35 ▼ -0.04 (-0.06%)

As of May 14, 2026 03:59 PM

Sector: Healthcare Industry: Medical Devices CIK: 0001099800

Market Cap 47.63 Bn

P/E 44.75

P/S 7.85

Div. Yield 0.00

ROIC (Qtr) 0.00

Total Debt (Qtr) 598.50 Mn

Revenue Growth (1y) (Qtr) 16.70

Add ratio to table...

About

Edwards Lifesciences Corporation is a global medical technology company that focuses on structural heart disease. The firm develops manufactures and markets therapies for aortic mitral tricuspid and pulmonary valve conditions. Its portfolio includes transcatheter and surgical solutions that aim to restore normal valve function and improve patient outcomes. Founded over six decades ago the company builds on a legacy of innovation begun by its founder Miles Lowell Edwards. Edwards Lifesciences continues to invest in research and clinical evidence...

Edwards Lifesciences Corporation is a global medical technology company that focuses on structural heart disease. The firm develops manufactures and markets therapies for aortic mitral tricuspid and pulmonary valve conditions. Its portfolio includes transcatheter and surgical solutions that aim to restore normal valve function and improve patient outcomes. Founded over six decades ago the company builds on a legacy of innovation begun by its founder Miles Lowell Edwards. Edwards Lifesciences continues to invest in research and clinical evidence to expand the use of its products across different risk groups and geographies.

Revenue is generated primarily from the sale of three product groups. The Transcatheter Aortic Valve Replacement group includes the SAPIEN family of valves and contributed about seventy four percent of net sales in 2025. The Transcatheter Mitral and Tricuspid Therapies group comprises repair and replacement systems such as PASCAL EVOQUE and SAPIEN M3 and accounted for roughly nine percent of net sales in 2025. The Surgical Structural Heart group consists of tissue valves and related devices and represented approximately seventeen percent of net sales in 2025. The company also earns revenue from associated services and support activities that complement its device sales.

The company reports its operations in three segments: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, and Surgical Structural Heart.

• Transcatheter Aortic Valve Replacement includes the SAPIEN family of transcatheter heart valves. These valves are delivered via catheter while the heart continues to beat and are used to treat severe aortic stenosis. The segment also covers related systems such as the Alterra system for pulmonary valve replacement in congenital heart disease.

• Transcatheter Mitral and Tricuspid Therapies comprises the PASCAL repair system the EVOQUE replacement system and the SAPIEN M3 replacement system. These technologies address mitral and tricuspid regurgitation through leaflet approximation or valve replacement and are approved in major markets including the United States Europe and Japan.

• Surgical Structural Heart focuses on surgical tissue valves and related conduits. Products include the INSPIRIS RESILIA aortic valve the KONECT RESILIA valved conduit and the MITRIS RESILIA mitral valve. The segment benefits from the RESILIA tissue technology which aims to improve durability and reduce calcification.

Edwards Lifesciences holds a leading position in the structural heart market. The company is frequently cited as a top competitor in transcatheter aortic valve replacement alongside Medtronic and Abbott. In transcatheter mitral and tricuspid therapies Edwards faces competition primarily from Abbott while many other firms pursue early stage projects. In the surgical heart valve arena Edwards contends with Medtronic and Abbott as well. Competitive advantages stem from a deep body of clinical evidence a reputation for product reliability and a global commercial infrastructure that supports rapid adoption of new technologies. The firm’s focus on generating real world data and expanding indications helps to maintain its market share and to drive guideline changes.

The company sells its products to hospitals health systems and cardiac care centers worldwide. Its customers include interventional cardiologists cardiac surgeons physicians and hospital administrators who make purchasing decisions for valve therapies. Edwards also works with group purchasing organizations and government agencies that negotiate contracts for medical devices. While the filing does not disclose individual customer names the base consists of a diverse mix of public and private healthcare providers across North America Europe Asia and other regions.

Investment thesis

Bull case

Edwards Lifesciences' unwavering focus on structural heart therapy remains a uniquely differentiated moat that has translated into consistent double‑digit revenue growth, with TAVR and TMTT each delivering robust performance. The company’s strategic emphasis on building a deep, evidence‑backed portfolio has secured clinical momentum that extends beyond the current product line, positioning it to capture increasing patient volumes as guidelines evolve worldwide. This disciplined approach has been paired with a proven capacity to scale production and field resources, ensuring that supply constraints will not hinder the uptake of new therapies such as the SAPIEN M3 and next‑generation PASCAL.
The 2026 guidance of 8‑10% sales growth, coupled with an EPS outlook that surpasses analyst consensus, reflects a clear confidence that the company's growth catalysts will materialize as planned. Edwards’ launch cadence for TMTT products—EVOQUE scaling, SAPIEN M3 rollout, and upcoming PASCAL in tricuspid therapy—creates a layered pipeline that should drive incremental revenue across the full spectrum of structural heart procedures. Each of these innovations builds on an established platform, reducing developmental risk and accelerating time‑to‑market.
Patient access initiatives, although represented by higher SG&A spending this quarter, are strategically aligned with early TAVR evidence that demonstrates lifetime management benefits. By front‑loading investment in education, early referral networks, and the American Heart Association partnership, Edwards is setting the stage for a more rapid conversion of eligible patients into treated cohorts. The early TAVR study, coupled with guideline changes that lower the age threshold and reduce watchful waiting, has already translated into increased procedural volumes, indicating that these access efforts are yielding tangible results.
The company's fiscal discipline is evident in its managed margin trajectory; operating margin expansion of 150 basis points is expected in 2026, with a projected 50‑100 basis point lift annually thereafter. Adjusted gross profit margins have held steady at 78‑79% despite increased manufacturing costs associated with rapid therapy launches, suggesting that pricing power remains intact. The ability to sustain margin growth while investing in patient access and expanding production capacity underscores a balanced capital allocation strategy that protects profitability.
Edwards’ strong cash position of approximately $3 billion, coupled with a $2 billion share repurchase authorization, provides ample flexibility for both organic investment and shareholder returns. The company’s share buyback program has already reached $900 million this year, reinforcing management’s conviction that the equity is undervalued. This financial resilience positions Edwards to navigate potential macroeconomic headwinds without compromising its growth trajectory.

Edwards Lifesciences' unwavering focus on structural heart therapy remains a uniquely differentiated moat that has translated into consistent double‑digit revenue growth, with TAVR and TMTT each delivering robust performance. The company’s strategic emphasis on building a deep, evidence‑backed portfolio has secured clinical momentum that extends beyond the current product line, positioning it to capture increasing patient volumes as guidelines evolve worldwide. This disciplined approach has been paired with a proven capacity to scale production and field resources, ensuring that supply constraints will not hinder the uptake of new therapies such as the SAPIEN M3 and next‑generation PASCAL.
The 2026 guidance of 8‑10% sales growth, coupled with an EPS outlook that surpasses analyst consensus, reflects a clear confidence that the company's growth catalysts will materialize as planned. Edwards’ launch cadence for TMTT products—EVOQUE scaling, SAPIEN M3 rollout, and upcoming PASCAL in tricuspid therapy—creates a layered pipeline that should drive incremental revenue across the full spectrum of structural heart procedures. Each of these innovations builds on an established platform, reducing developmental risk and accelerating time‑to‑market.
Patient access initiatives, although represented by higher SG&A spending this quarter, are strategically aligned with early TAVR evidence that demonstrates lifetime management benefits. By front‑loading investment in education, early referral networks, and the American Heart Association partnership, Edwards is setting the stage for a more rapid conversion of eligible patients into treated cohorts. The early TAVR study, coupled with guideline changes that lower the age threshold and reduce watchful waiting, has already translated into increased procedural volumes, indicating that these access efforts are yielding tangible results.
The company's fiscal discipline is evident in its managed margin trajectory; operating margin expansion of 150 basis points is expected in 2026, with a projected 50‑100 basis point lift annually thereafter. Adjusted gross profit margins have held steady at 78‑79% despite increased manufacturing costs associated with rapid therapy launches, suggesting that pricing power remains intact. The ability to sustain margin growth while investing in patient access and expanding production capacity underscores a balanced capital allocation strategy that protects profitability.
Edwards’ strong cash position of approximately $3 billion, coupled with a $2 billion share repurchase authorization, provides ample flexibility for both organic investment and shareholder returns. The company’s share buyback program has already reached $900 million this year, reinforcing management’s conviction that the equity is undervalued. This financial resilience positions Edwards to navigate potential macroeconomic headwinds without compromising its growth trajectory.

Bear case

The recent withdrawal of Edwards’ anti‑copycat policy, while resolving a regulatory challenge, signals an increase in competitive pressures that could erode market share. The policy had served to protect intellectual property and limit the entry of low‑cost competitors; its removal may accelerate the proliferation of alternative valve platforms, especially from emerging markets that are less constrained by U.S. and EU patent landscapes. This heightened competition could compress pricing and force the company to reduce its market share if it cannot maintain its cost advantage.
Although the company has managed to sustain gross margins, its SG&A expense rose to 38% of sales from 35% the previous year, largely due to amplified patient‑access spend. The capital intensity required to sustain early TAVR uptake—through field force expansion, education, and the American Heart Association partnership—has increased operating leverage. Should the expected conversion of access initiatives into incremental volume fail to materialize at the projected rate, margin erosion could accelerate, undermining the company’s ability to fund its pipeline and return capital to shareholders.
The company’s tax rate, currently 29%, is above management’s expectation of 17‑19% excluding special items, primarily due to Pillar Two and country mix effects. A higher effective tax burden reduces free cash flow, potentially limiting the scope for future acquisitions or further share buybacks. Moreover, the ongoing scrutiny from EU antitrust regulators and the need to adjust compliance structures could introduce additional indirect costs that are difficult to quantify and may further compress profitability.
The 2026 sales guidance of 8‑10% hinges on the assumption that early TAVR evidence will continue to drive demand across all markets, yet the adoption curve for asymptomatic or early‑stage patients remains uncertain. While guidelines have been updated, the clinical community requires time to integrate these changes into practice patterns, and reimbursement frameworks may lag. Delays in widespread uptake would result in lower-than‑expected procedural volumes, directly impacting revenue growth.
The GennaValve acquisition did not close, exposing the company to a significant one‑time charge that impacted GAAP EPS and signaled a potential risk in M&A execution. The failure to integrate the acquisition may have drained financial resources and diverted management attention from core product development. Future attempts to acquire complementary technologies could be viewed with caution by investors, potentially increasing the cost of capital or deterring strategic partnerships.

The recent withdrawal of Edwards’ anti‑copycat policy, while resolving a regulatory challenge, signals an increase in competitive pressures that could erode market share. The policy had served to protect intellectual property and limit the entry of low‑cost competitors; its removal may accelerate the proliferation of alternative valve platforms, especially from emerging markets that are less constrained by U.S. and EU patent landscapes. This heightened competition could compress pricing and force the company to reduce its market share if it cannot maintain its cost advantage.
Although the company has managed to sustain gross margins, its SG&A expense rose to 38% of sales from 35% the previous year, largely due to amplified patient‑access spend. The capital intensity required to sustain early TAVR uptake—through field force expansion, education, and the American Heart Association partnership—has increased operating leverage. Should the expected conversion of access initiatives into incremental volume fail to materialize at the projected rate, margin erosion could accelerate, undermining the company’s ability to fund its pipeline and return capital to shareholders.
The company’s tax rate, currently 29%, is above management’s expectation of 17‑19% excluding special items, primarily due to Pillar Two and country mix effects. A higher effective tax burden reduces free cash flow, potentially limiting the scope for future acquisitions or further share buybacks. Moreover, the ongoing scrutiny from EU antitrust regulators and the need to adjust compliance structures could introduce additional indirect costs that are difficult to quantify and may further compress profitability.
The 2026 sales guidance of 8‑10% hinges on the assumption that early TAVR evidence will continue to drive demand across all markets, yet the adoption curve for asymptomatic or early‑stage patients remains uncertain. While guidelines have been updated, the clinical community requires time to integrate these changes into practice patterns, and reimbursement frameworks may lag. Delays in widespread uptake would result in lower-than‑expected procedural volumes, directly impacting revenue growth.
The GennaValve acquisition did not close, exposing the company to a significant one‑time charge that impacted GAAP EPS and signaled a potential risk in M&A execution. The failure to integrate the acquisition may have drained financial resources and diverted management attention from core product development. Future attempts to acquire complementary technologies could be viewed with caution by investors, potentially increasing the cost of capital or deterring strategic partnerships.

Segments Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	145.93 Bn	23.33	3.23	34.05 Bn
2	SYK	Stryker Corp	115.71 Bn	34.62	4.58	14.72 Bn
3	MDT	Medtronic plc	97.69 Bn	21.17	2.75	28.07 Bn
4	BSX	Boston Scientific Corp	78.71 Bn	22.00	3.82	11.03 Bn
5	EW	Edwards Lifesciences Corp	47.63 Bn	44.75	7.85	0.60 Bn
6	PHG	Koninklijke Philips Nv	29.38 Bn	13,009.40	1.46	8.07 Bn
7	DXCM	Dexcom Inc	22.72 Bn	24.58	4.72	-
8	STE	STERIS plc	20.71 Bn	29.06	3.55	1.90 Bn

Research Tools